DCGI approved the use of Russia’s Sputnik V to fight COVID-19 and will soon be used in India.
After Covishield and Covaxin, it will be the third vaccine to be available to vaccinate people against COVID-19. This vaccine has been developed in Gamaleya Research Center for Epidemiology and Microbiology, Moscow, and was also the first officially registered vaccine for COVID-19.
Here is how this vaccine will stand against the already existing vaccines in India and the key features of Sputnik V.
- Sputnik V is also based on the adenovirus vector platform, the difference is that it uses two human adenoviruses and Covishield uses one.
- There have been no adverse effects of Sputnik V that have been detected and only mild symptoms occur after the dose is administered. Covishield has been criticized for causing blood clots in patients in rare circumstances.
- Sputnik V is 91.6 percent effective.
- This vaccine is available in two forms, liquid and lyophilized. It is to be stored at the temperature of 2°C-8°C.
Many countries have approved the use of the Sputnik V vaccine and once it starts to be produced in India, the production cost is expected to come down and so is the price at which it will be sold.
